Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2016 - 2026)

Madrigal Pharmaceuticals (MDGL) has 11 years of Interest & Investment Income data on file, last reported at $8.2 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 12.03% year-over-year to $8.2 million in Q1 2026; TTM through Mar 2026 was $36.2 million, a 24.02% decrease from a year earlier, with the FY2025 full-year figure at $37.4 million, down 19.91% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $8.2 million, down from $9.5 million in the prior quarter.
• Over the last five years, Interest & Investment Income for MDGL reached as high as $14.2 million in Q2 2024 and fell as low as $69000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $6.7 million across 5 years, with a median of $8.2 million in 2026.
• Across the five-year window, Interest & Investment Income sank 56.88% in 2022 and jumped 5372.46% in 2023, its largest moves.
• Year by year, Interest & Investment Income stood at $1.1 million in 2022, then jumped by 732.06% to $9.0 million in 2023, then increased by 23.75% to $11.1 million in 2024, then retreated by 14.62% to $9.5 million in 2025, then declined by 12.86% to $8.2 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $8.2 million in Q1 2026, $9.5 million in Q4 2025, and $10.3 million in Q3 2025.